157 related articles for article (PubMed ID: 30685793)
1. Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Baron-Hay S; Aapro M; Bernareggi A; Schwartzberg L
Support Care Cancer; 2019 Apr; 27(4):1309-1317. PubMed ID: 30685793
[TBL] [Abstract][Full Text] [Related]
2. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
Navari RM; Binder G; Bonizzoni E; Clark-Snow R; Olivari S; Roeland EJ
Future Oncol; 2021 Aug; 17(23):3027-3035. PubMed ID: 33878896
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers.
Chen R; Wang H; Zhong W; Chessari S; Lanzarotti C; Bernareggi A; Hu P
Cancer Chemother Pharmacol; 2021 Mar; 87(3):387-396. PubMed ID: 33386423
[TBL] [Abstract][Full Text] [Related]
4. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
Shirley M
Drugs; 2021 Jul; 81(11):1331-1342. PubMed ID: 34292534
[TBL] [Abstract][Full Text] [Related]
5. NEPA as antiemetic prophylaxis after failure of 5HT
Valerio MR; Gebbia V; Borsellino N; Vecchia M; Serretta V; Pardo S; Cipolla C; Galanti D
J Oncol Pharm Pract; 2021 Apr; 27(3):609-613. PubMed ID: 32507099
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L
Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742
[TBL] [Abstract][Full Text] [Related]
7. NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.
De Luca R; Volpe C; Mistretta O; Paci R; Ferrera G; Caputo V; Rosati G; Cicero G
Eur Rev Med Pharmacol Sci; 2021 Aug; 25(16):5310-5317. PubMed ID: 34486707
[TBL] [Abstract][Full Text] [Related]
8. Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
Caputo R; Cazzaniga ME; Sbrana A; Torrisi R; Paris I; Giordano M; Montesarchio V; Guarneri V; Amaducci L; Bilancia D; Cilenti G; Fabi A; Collovà E; Schirone A; Bonizzoni E; Celio L; De Placido S; De Laurentiis M
BMC Cancer; 2020 Mar; 20(1):232. PubMed ID: 32188417
[TBL] [Abstract][Full Text] [Related]
9. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F
Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177
[TBL] [Abstract][Full Text] [Related]
10. Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.
Aapro M; Jordan K; Scotté F; Celio L; Karthaus M; Roeland E
Curr Cancer Drug Targets; 2022; 22(10):806-824. PubMed ID: 35570542
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
Botteman M; Nickel K; Corman S; Turini M; Binder G
Support Care Cancer; 2020 Feb; 28(2):857-866. PubMed ID: 31161436
[TBL] [Abstract][Full Text] [Related]
12. Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life.
Karthaus M; Oskay-Özcelik G; Wülfing P; Hielscher C; Guth D; Zahn MO; Flahaut E; Schilling J
Future Oncol; 2020 May; 16(14):939-953. PubMed ID: 32298187
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of netupitant/palonosetron in preventing nausea and vomiting in diffuse large B cell lymphoma patients undergoing R-CHOP chemotherapy.
Kwak K; Park Y; Kim BS; Kang KW
Sci Rep; 2024 May; 14(1):11229. PubMed ID: 38755279
[TBL] [Abstract][Full Text] [Related]
14. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.
Schwartzberg L; Navari R; Clark-Snow R; Arkania E; Radyukova I; Patel K; Voisin D; Rizzi G; Wickham R; Gralla RJ; Aapro M; Roeland E
Oncologist; 2020 Mar; 25(3):e589-e597. PubMed ID: 32162813
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin's lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation.
Di Renzo N; Musso M; Scimè R; Cupri A; Perrone T; De Risi C; Pastore D; Guarini A; Mengarelli A; Benedetti F; Mazza P; Capria S; Chiusolo P; Cupelli L; Federico V; Bozzoli V; Messa AR; Matera R; Seripa D; Codega P; Bonizzoni E; Specchia G
Support Care Cancer; 2022 Feb; 30(2):1521-1527. PubMed ID: 34533630
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of intravenous NEPA, a fixed NK
Aapro M; Navari RM; Roeland E; Zhang L; Schwartzberg L
Crit Rev Oncol Hematol; 2021 Jan; 157():103143. PubMed ID: 33260048
[TBL] [Abstract][Full Text] [Related]
17. Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65 years) fit for cisplatin: A sub-analysis from a phase 3 study.
Celio L; Bartsch R; Aapro M
J Geriatr Oncol; 2023 Jul; 14(6):101537. PubMed ID: 37290207
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting.
Vaswani B; Dattatreya PS; Bhagat S; Patil S; Barkate H
BMC Cancer; 2021 May; 21(1):601. PubMed ID: 34034703
[TBL] [Abstract][Full Text] [Related]
19. Real-world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed-dose combination to prevent chemotherapy-induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy.
Md Yusof M; Abdullah MM; Yap BK; Ng SC; Low JSH; Lam KS; Ahmad Badruddin RBA; Lai CNB; Lau KL; Chong KJ; Nonis JG; Ahmad Annuar MA; Abdul Rahman MHFB
Asia Pac J Clin Oncol; 2022 Aug; 18(4):419-427. PubMed ID: 34811924
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
